Results 41 to 50 of about 58,247 (201)

Epidemiological aspects of allergic conjunctivitis

open access: yesAllergology International, 2020
The prevalence of ocular allergies has been increasing worldwide for the past several decades. The geographical distribution and hot spots of rhinoconjunctivitis have been documented in a global survey by the International Study of Asthma and Allergies ...
Dai Miyazaki   +8 more
doaj   +1 more source

Therapeutic effect of 0.1% Tacrolimus Eye Ointment in Allergic Ocular Diseases [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2016
Introduction: Allergic Ocular Diseases (AODs) like Atopic Keratoconjunctivitis (AKC) and Vernal Keratoconjunctivitis (VKC) are chronic forms of ocular allergy that can cause severe visual complications. Pathogenesis of AODs is uncertain and treatment
RAKESH K BAROT   +5 more
doaj   +1 more source

Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases

open access: yesAllergy, Asthma & Clinical Immunology, 2021
Background Because atopic dermatitis does not heal completely, associated severe atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) often require long-term treatment.
Hiroyuki Yazu   +4 more
doaj   +1 more source

Topical cyclosporine for atopic keratoconjunctivitis. [PDF]

open access: yesCochrane Database Syst Rev, 2012
Atopic keratoconjunctivitis (AKC) is a chronic ocular surface non-infectious inflammatory condition that atopic dermatitis patients may suffer at any time point in the course of their dermatologic disease and is independent of its degree of severity. AKC is usually not self resolving and it poses a higher risk of corneal injuries and severe sequelae ...
González-López JJ   +4 more
europepmc   +4 more sources

Japanese Guideline for Allergic Conjunctival Diseases

open access: yesAllergology International, 2011
The definition, classification, pathogenesis, test methods, clinical findings, criteria for diagnosis, and therapies of allergic conjunctival disease are summarized based on the Guidelines for Clinical Management of Allergic Conjunctival Disease (Second ...
Etsuko Takamura   +13 more
doaj   +1 more source

Positive regulation of innate immune response by miRNA-let-7a-5p

open access: yesFrontiers in Genetics, 2023
Background: We have hypothesized that different factors are involved in the severity of ACD and AD because some but not all patients with atopic dermatitis (AD) present with allergic conjunctival disease (ACD) including severe types such as atopic ...
Mayumi Ueta   +8 more
doaj   +1 more source

Incorporating the Competencies of Evidence‐Based Veterinary Medicine Focused on Pharmacotherapeutics Into Clinical Rotations for Small Animal Dermatology and Food Animal Medicine and Surgery at a Veterinary Medical Teaching Hospital in the US

open access: yesJournal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Building the skills and knowledge necessary to practice evidence‐based veterinary medicine (EBVM) should occur throughout the veterinary curriculum. Operationalizing EBVM includes asking a clinical question in PICO format, searching the biomedical literature for evidence, critically appraising the evidence, and applying the evidence to make a ...
Virginia R. Fajt   +4 more
wiley   +1 more source

Loss-of-function variants of the filaggrin gene are associated with atopic eczema and associated phenotypes in Swedish families [PDF]

open access: yes, 2008
Recent studies have identified 2 loss-of-function variants, R501X and 2282del4, in the filaggrin gene as predisposing factors in the development of eczema.
Link, Jenny   +15 more
core   +1 more source

Japanese guidelines for allergic conjunctival diseases 2017

open access: yesAllergology International, 2017
The definition, classification, pathogenesis, test methods, clinical findings, criteria for diagnosis, and therapies of allergic conjunctival disease are summarized based on the Guidelines for Clinical Management of Allergic Conjunctival Disease (Second ...
Etsuko Takamura   +13 more
doaj   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

open access: yesAustralasian Journal of Dermatology, Volume 67, Issue 5, Page 301-308, August 2026.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy